Halozyme Therapeutics (HALO)'s 30-day implied volatility (IV30) was 42.0% at the close on November 16, 2026, up from 37.9% the day before, against a 52-week range of 25.4% to 56.3%. Its 20-day historical volatility was 32.3%.
Data as of November 16, 2026.